Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can urine sodium levels guide better heart failure treatment?

NCT ID NCT07263035

Symptom relief Sponsor: Lakeland Regional Health Systems, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adjusting the dose of a diuretic (water pill) based on urine sodium levels can improve outcomes for people hospitalized with acute heart failure. Researchers will compare two urine sodium targets against standard care in 600 adults. The goal is to see if this approach increases fluid removal, shortens hospital stays, and reduces readmissions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Furosemide (Lasix) intravenous solution
What this could lead to
If successful, this could lead to a more effective way to use existing diuretics to reduce hospital stays and readmissions for heart failure patients.
What could go wrong
This is a single-center trial, so results may not apply broadly. The approach is still experimental and may not improve outcomes over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The study will target adults 18 years of age or older admitted to Lakeland Regional Medical Center who: * Have a primary diagnosis of acute decompensated heart failure, and * Have at least one of the following signs of hypervolemia: * Bilateral lower extremity pitting edema * Jugular venous distension * Hepatojugular reflex * Crackles on pulmonary exam, or * Chest x-ray demonstrating pulmonary edema or pleural effusions Exclusion Criteria: * Exclusion criteria include: * Admission to the intensive care unit * Presence of ST-elevated myocardial infarction * Presence of type 1 non-ST elevated myocardial infarction * Dyspnea primarily due to non-cardiac cause as judged by the emergency medicine physician or admitting physician * Use of supplemental oxygen totaling at least 3 L per minute or greater at baseline * Anuria * End-stage renal disease per KDIGO criteria * Dialysis use

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute decompensated heart failure are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute heart failure (AHF) Heart failure Heart failure - nyha ii - iv Heart failure, acute

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Lakeland Regional Hospital

    RECRUITING

    Lakeland, Florida, 33805, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.